Transgenic animals are an important tool in cardiovascular research and much of the transgenic animal modeling is done in mice. Mice, however, present unique problems with very fast heart rates (500-600 beats per minute), and very small size of the heart (4-6 millimeter diameter). We have developed surgical techniques to appropriately perform open-chest surgery to cause coronary artery occlusion and reperfusion, inject agents into the myocardium and/or occlude the transverse aorta. We have developed techniques to measure blood flow velocity by using pulsed Doppler instrumentation in a non-invasive procedure, M-mode echocardiography designed to measure cardiac dimensions and motion in mice and nuclear imaging for ejection fraction and whole heart function. Hence, we have the technology to study the development of cardiac abnormalities with various therapies and studying the hemodynamics and heart function in a non-invasive longitudinal manner in mice, rats or larger animals. The formation of the transgenic animals will also be carried out by various laboratories who model transgenic animals. The transgenic modeling will be coordinated with our ability to measure physiological function of these animals with time.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
3P50HL054313-08S1
Application #
6569682
Study Section
Project Start
2002-02-01
Project End
2003-01-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
$184,963
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Nassif, Michael E; LaRue, Shane J; Raymer, David S et al. (2016) Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circ Heart Fail 9:
Adamo, Luigi; Nassif, Michael; Tibrewala, Anjan et al. (2015) The Heartmate Risk Score predicts morbidity and mortality in unselected left ventricular assist device recipients and risk stratifies INTERMACS class 1 patients. JACC Heart Fail 3:283-90
Nassif, Michael E; Patel, Jayendrakumar S; Shuster, Jerrica E et al. (2015) Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail 3:146-53
Mann, Douglas L; Mochly-Rosen, Daria (2013) Translational medicine: mitigating risks for investigators. Nat Rev Drug Discov 12:327-8
Lombardi, Raffaella; Rodriguez, Gabriela; Chen, Suet Nee et al. (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119:1398-407
Lombardi, Raffaella; Bell, Achim; Senthil, Vinitha et al. (2008) Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res 79:109-17
Mann, Douglas L; Bozkurt, Biykem; Torre-Amione, Guillermo et al. (2008) Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci 1:142-5
Daw, E W; Lu, Y; Marian, A J et al. (2008) Identifying modifier loci in existing genome scan data. Ann Hum Genet 72:670-5
Marian, Ali J (2008) Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol 23:199-205
Daw, E Warwick; Chen, Suet Nee; Czernuszewicz, Grazyna et al. (2007) Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet 16:2463-71

Showing the most recent 10 out of 69 publications